Genflow Biosciences Company
Genflow Biosciences research ways to work with the SIRT6 gene that is recognized as a master regulator of healthy aging. SIRT6 overexpression has been shown to lead to a healthy lifespan extension in both male and female mice. Genflow Biosciences intends to promote healthy aging by providing extra copies of a variant of the Human SIRT6 gene found in centenarians. Genflow Biosciences is developing an ethical, safe and efficient gene delivery system to deliver this centenarian variant of the SIRT6 gene.
Last Funding Type:
seed round
Funding Status:
Seed
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2020
Investor Type:
Seed
Last Funding Date:
Jan 15, 2021
Employee Number:
1-10
Number Of Exists:
1-10
Investors Number:
1
Industry:
Biotechnology, Gene therapy